BR0312896A - Glicanos e glicopeptìdeos de campylobacter - Google Patents

Glicanos e glicopeptìdeos de campylobacter

Info

Publication number
BR0312896A
BR0312896A BR0312896-2A BR0312896A BR0312896A BR 0312896 A BR0312896 A BR 0312896A BR 0312896 A BR0312896 A BR 0312896A BR 0312896 A BR0312896 A BR 0312896A
Authority
BR
Brazil
Prior art keywords
galnac
glycan
campylobacter
bac
antibodies
Prior art date
Application number
BR0312896-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Noel M Young
Jean Robert Brisson
John Francis Kelly
David C Watson
Christine M Szymanski
Harold C Jarrell
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Publication of BR0312896A publication Critical patent/BR0312896A/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56922Campylobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/105Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BR0312896-2A 2002-08-01 2003-07-30 Glicanos e glicopeptìdeos de campylobacter BR0312896A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39973502P 2002-08-01 2002-08-01
PCT/CA2003/001156 WO2004013151A2 (en) 2002-08-01 2003-07-30 Campylobacter glycans and glycopeptides

Publications (1)

Publication Number Publication Date
BR0312896A true BR0312896A (pt) 2005-06-14

Family

ID=31495764

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312896-2A BR0312896A (pt) 2002-08-01 2003-07-30 Glicanos e glicopeptìdeos de campylobacter

Country Status (9)

Country Link
US (1) US7598354B2 (enExample)
EP (1) EP1527080B1 (enExample)
JP (1) JP4718174B2 (enExample)
CN (1) CN1671722A (enExample)
AU (1) AU2003254665C1 (enExample)
BR (1) BR0312896A (enExample)
CA (1) CA2494223C (enExample)
ES (1) ES2391525T3 (enExample)
WO (1) WO2004013151A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
CA2477794C (en) 2002-03-07 2013-08-20 Eidgenoessische Technische Hochschule Zuerich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
AU2002952121A0 (en) * 2002-10-17 2002-10-31 Alchemia Limited Novel carbohydrate based anti-bacterials
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20080015142A1 (en) * 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
JP5356807B2 (ja) 2005-05-11 2013-12-04 アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ 原核細胞由来の組み換えn−グリコシル化タンパク質
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー/エス ポリペプチドコンジュゲートの精製方法
RS52845B (sr) 2007-04-03 2013-12-31 Biogenerix Ag Postupci tretmana korišćenjem glikopegiliranog g-csf
JP5876649B2 (ja) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーratiopharm GmbH ヌクレオチド糖の改良製造法
US8999668B2 (en) 2008-01-03 2015-04-07 Cornell Research Foundation, Inc. Glycosylated protein expression in prokaryotes
EP2242505A4 (en) * 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
HRP20181259T1 (hr) 2008-02-20 2018-10-05 Glaxosmithkline Biologicals S.A. Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
PL2411503T3 (pl) * 2009-03-27 2018-01-31 Eidgenoessische Technische Hochschule Zuerich Salmonella enterica prezentująca n-glikan z c. jejuni lub jego pochodne
AU2010322454B2 (en) 2009-11-19 2016-05-19 Glaxosmithkline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
JP5925699B2 (ja) * 2010-02-11 2016-05-25 ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ N結合型グリカン化合物
US8841099B2 (en) * 2010-04-20 2014-09-23 National Research Council Of Canada Cell-based production of nonulosonates
ES2844596T3 (es) 2010-05-06 2021-07-22 Glaxosmithkline Biologicals Sa Vacunas de bioconjugados de bacterias grampositivas capsulares
US9308246B2 (en) 2010-05-28 2016-04-12 The United States Of America As Represented By The Secretary Of The Navy Capsule composition for use as immunogen against Campylobacter jejuni
JP6135046B2 (ja) * 2012-04-20 2017-05-31 株式会社島津製作所 糖ペプチドの質量分析法
EP2991675B1 (en) 2013-04-05 2019-07-24 The Governors of the University of Alberta Campylobacter vaccine
EP4205553A1 (en) * 2015-01-26 2023-07-05 DSM Nutritional Products, LLC Oligosaccharide compositions for use animal feed and methods of producing thereof
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
US11898187B2 (en) 2017-08-15 2024-02-13 Northwestern University Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
WO2019119134A1 (en) * 2017-12-19 2019-06-27 The Governors Of The University Of Alberta Clostridium perfringens surface glycans and uses thereof
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
US11725224B2 (en) 2018-04-16 2023-08-15 Northwestern University Methods for co-activating in vitro non-standard amino acid (nsAA) incorporation and glycosylation in crude cell lysates
WO2020072127A2 (en) 2018-08-03 2020-04-09 Northwestern University On demand, portable, cell-free molecular sensing platform
US12404533B2 (en) 2019-01-11 2025-09-02 Northwestern University Bioconjugate vaccines' synthesis in prokaryotic cell lysates
US12325884B2 (en) 2019-03-04 2025-06-10 Northwestern University Riboswitch-based fluoride sensing in cell-free extract
US12226410B2 (en) 2019-10-18 2025-02-18 Northwestern University Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
US20240287564A1 (en) * 2021-06-07 2024-08-29 The University Of British Columbia Acholetin biopolymers and methods for enzymatic synthesis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5200344A (en) * 1990-11-13 1993-04-06 Blaser Martin J Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens
WO1995005850A1 (en) * 1993-08-27 1995-03-02 Enteric Research Laboratories, Inc. Campylobacter jejuni antigens, and methods for their production and use
WO1996007753A1 (en) * 1994-09-06 1996-03-14 Bioflexin Ab Amino acid conjugate
US5840547A (en) * 1995-01-05 1998-11-24 Ramot University Authority For Applied Research & Indfustrial Development Ltd. Bioemulsifiers
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
US6699705B2 (en) * 1999-02-01 2004-03-02 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
AU3513500A (en) * 1999-03-05 2000-09-21 Trustees Of Tufts College Emulsan and emulsan analogs immunization formulations and use
US6512014B2 (en) * 2000-12-13 2003-01-28 Ramot University Authority For Applied Research And Industrial Development Limited Compositions containing bioemulsifiers and a method for their preparation
ES2561985T3 (es) * 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
US9084809B2 (en) * 2005-09-21 2015-07-21 The United States Of America As Represented By The Secretary Of The Navy Immunogenic capsule composition for use as a vaccine component against Campylobacter jejuni

Also Published As

Publication number Publication date
US20060165728A1 (en) 2006-07-27
AU2003254665C1 (en) 2010-08-19
JP2005534752A (ja) 2005-11-17
US7598354B2 (en) 2009-10-06
ES2391525T3 (es) 2012-11-27
JP4718174B2 (ja) 2011-07-06
EP1527080B1 (en) 2012-06-20
AU2003254665B2 (en) 2010-01-28
CA2494223A1 (en) 2004-02-12
WO2004013151A3 (en) 2004-07-01
AU2003254665A1 (en) 2004-02-23
EP1527080A2 (en) 2005-05-04
WO2004013151A2 (en) 2004-02-12
CA2494223C (en) 2012-10-02
CN1671722A (zh) 2005-09-21

Similar Documents

Publication Publication Date Title
BR0312896A (pt) Glicanos e glicopeptìdeos de campylobacter
León-Sicairos et al. Amoebicidal activity of milk, apo-lactoferrin, sIgA and lysozyme
Hoyle The influenza viruses
Paba et al. Proteomic analysis of the human pathogen Trypanosoma cruzi
Paniker et al. Infection with A2 Hong Kong influenza virus in domestic cats
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
Bittar et al. Effects of injectable trace minerals on the immune response to Mannheimia haemolytica and Pasteurella multocida following vaccination of dairy calves with a commercial attenuated-live bacterin vaccine
Hajnicka et al. Tick salivary gland extracts promote virus growth in vitro
US20200069781A1 (en) Immunogenic lhrh composition and use thereof in pigs
Acosta et al. Structural and immunological characterization of sulphatides: relevance of sulphate moieties in Trypanosoma cruzi glycoconjugates
CN116036074B (zh) 山奈酚在抑制痘病毒及预防或治疗痘病毒感染的药物制备中的应用
Neurath et al. Solubilization and some properties of the erythrocyte receptor for adenovirus type 7 haemagglutinin
Tazuke et al. Protective mechanism of glutamine on the expression of proliferating cell nuclear antigen after cisplatin-induced intestinal mucosal injury
Housawi et al. A close comparative study on the response of sheep and goats to experimental orf infection
CN1341150A (zh) 疟疾疫苗
Qureshi et al. A novel phage based marker vaccine and DI VA assay for hemorrhagic septicemia in bovines
BR0001559A (pt) Vacina para a prevenção da colonização de campylobacter em animais, proteìna antigênica de campylobacter, uso de uma proteìna antigênica, vacina para a prevenção da colonização de campylobacter jejuni em galináceos, uso de anticorpos contra uma cepa de campylobacter sem flagelos, ou contra a proteìna antigênica, e, processo para a preparação de uma vacina
US12285479B2 (en) Anti-coronavirus vaccines
US20240218020A1 (en) Peptides inhibiting covid-19
Baraitareanu et al. Biological technique used as alternative method in the vaccine potency assays: in-house sandwich ELISA for Rabbit haemorrhagic disease virus
Zhang et al. Seroprevalence of antibodies against foot-and-mouth disease vaccine in yaks in China
Firouzi et al. Effect of heat and cold stress on humoral immunity in mice
BRPI0503187B1 (pt) Composição compreendendo fucose manose ligand (fml) e saponina, para uso como uma vacina bloqueadora contra a transmissão de leishmaniose visceral canina
Woolums Novel immunological approaches to improve cattle health
Meseko et al. Detection of Haemagglutination inhibition antibody to Pandemic and Classical Swine Influenza Virus in Commercial Piggery in Lagos Nigeria

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012.